Skip to main content
EJNMMI Research
Fig. 4 | EJNMMI Research

Fig. 4

From: Early 18F-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Fig. 4

Imaging studies and percentage variation of 18F-FDG uptake in nude mice bearing H1975 and H1993 xenografts. a SUVmax of H1975 and H1993 xenografts obtained from baseline and post-treatment scans are expressed as mean ± SE. b Percentage variations of 18F-FDG uptake in H1975- and H1993-tumor-bearing animals in response to each treatment. Significant differences versus vehicle-treated animals were indicated with *p < 0.05, **p < 0.01, and ***p < 0.001; significant differences versus erlotinib-treated animals were indicated with # p < 0.05. c Representative transaxial 18F-FDG PET images of mice before (left panels) and 3 days after (right panels) treatment with 50 mg/kg erlotinib in H1975 (upper panels) and H1993 (lower panels) xenografts

Back to article page